These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26659791)

  • 1. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
    Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
    Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
    Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
    Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
    Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Takeuchi T; Tanaka Y; Matsumura R; Saito K; Yoshimura M; Amano K; Atsumi T; Suematsu E; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):93-100. PubMed ID: 30791804
    [No Abstract]   [Full Text] [Related]  

  • 10. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
    Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
    Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
    Witcher J; Fleischmann R; Chindalore VL; Hansen RJ; Hu L; Radtke D; Voelker J; Gomez E; McColm J
    Br J Clin Pharmacol; 2016 May; 81(5):908-17. PubMed ID: 26648084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus.
    Zhou X; Lee TI; Zhu M; Ma P
    Drugs R D; 2021 Dec; 21(4):407-417. PubMed ID: 34628605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
    Jonsson EN; Xie R; Marshall SF; Arends RH
    Br J Clin Pharmacol; 2016 Apr; 81(4):688-99. PubMed ID: 26613544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus.
    Struemper H; Chen C; Cai W
    J Clin Pharmacol; 2013 Jul; 53(7):711-20. PubMed ID: 23681782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
    Shen T; James DE; Krueger KA
    Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
    Li C; Shoji S; Beebe J
    Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.
    Chen P; Vu T; Narayanan A; Sohn W; Wang J; Boedigheimer M; Welcher AA; Sullivan B; Martin DA; Ruixo JJ; Ma P
    Pharm Res; 2015 Feb; 32(2):640-53. PubMed ID: 25213774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.
    Greth W; Robbie GJ; Brohawn P; Hultquist M; Yao B
    Immunotherapy; 2017 Jan; 9(1):57-70. PubMed ID: 28000522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.